Cargando…

Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients

Purpose: This meta-analysis was aimed to evaluate the role of postoperative concurrent chemoradiotherapy (post-CCRT) for esophageal cancer patients after surgery. Methods: We systematically searched PubMed, PMC, EMBASE, Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Jingjing, Chang, Joe Y., Sun, Xin, Men, Yu, Zeng, Hongmei, Hui, Zhouguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820926/
https://www.ncbi.nlm.nih.gov/pubmed/29483964
http://dx.doi.org/10.7150/jca.20940
_version_ 1783301460589543424
author Kang, Jingjing
Chang, Joe Y.
Sun, Xin
Men, Yu
Zeng, Hongmei
Hui, Zhouguang
author_facet Kang, Jingjing
Chang, Joe Y.
Sun, Xin
Men, Yu
Zeng, Hongmei
Hui, Zhouguang
author_sort Kang, Jingjing
collection PubMed
description Purpose: This meta-analysis was aimed to evaluate the role of postoperative concurrent chemoradiotherapy (post-CCRT) for esophageal cancer patients after surgery. Methods: We systematically searched PubMed, PMC, EMBASE, Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure and Wanfang databases. Studies which compared CCRT with non-CCRT treatment for esophageal cancer patients after surgery were eligible. Outcomes of interest were odds ratios (OR) for overall survival (OS), local-regional recurrence rate, distant metastasis rate and adverse-event rate. Results: Thirteen studies with 2165 patients were included in this meta-analysis. Post-CCRT significantly improved OS for esophageal cancer patients. Comparing the CCRT group with the non-CCRT one, the OR and 95% confidence interval (CI) for 1-year, 3-year and 5-year OS were 1.66 [1.30-2.11], 1.50 [1.24-1.81] and 1.54 [1.22-1.94], respectively. The local-regional recurrence rate was significantly reduced in the CCRT group (OR=0.58, 95% CI=0.46-0.72), but no significant difference was observed in the distant metastasis rate between the CCRT and non-CCRT groups (OR=0.94, 95% CI=0.68-1.30). Post-CCRT didn't increase the risk of pneumonitis, anastomotic stenosis or severe hematologic toxicities. Mild esophagitis in the CCRT group was increased but could be well tolerated. Conclusions: This meta-analysis based on the largest-scale of published literature confirms that post-CCRT yields significant survival benefit and improves local-regional control with tolerable toxicity for patients with esophageal carcinoma.
format Online
Article
Text
id pubmed-5820926
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-58209262018-02-26 Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients Kang, Jingjing Chang, Joe Y. Sun, Xin Men, Yu Zeng, Hongmei Hui, Zhouguang J Cancer Research Paper Purpose: This meta-analysis was aimed to evaluate the role of postoperative concurrent chemoradiotherapy (post-CCRT) for esophageal cancer patients after surgery. Methods: We systematically searched PubMed, PMC, EMBASE, Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure and Wanfang databases. Studies which compared CCRT with non-CCRT treatment for esophageal cancer patients after surgery were eligible. Outcomes of interest were odds ratios (OR) for overall survival (OS), local-regional recurrence rate, distant metastasis rate and adverse-event rate. Results: Thirteen studies with 2165 patients were included in this meta-analysis. Post-CCRT significantly improved OS for esophageal cancer patients. Comparing the CCRT group with the non-CCRT one, the OR and 95% confidence interval (CI) for 1-year, 3-year and 5-year OS were 1.66 [1.30-2.11], 1.50 [1.24-1.81] and 1.54 [1.22-1.94], respectively. The local-regional recurrence rate was significantly reduced in the CCRT group (OR=0.58, 95% CI=0.46-0.72), but no significant difference was observed in the distant metastasis rate between the CCRT and non-CCRT groups (OR=0.94, 95% CI=0.68-1.30). Post-CCRT didn't increase the risk of pneumonitis, anastomotic stenosis or severe hematologic toxicities. Mild esophagitis in the CCRT group was increased but could be well tolerated. Conclusions: This meta-analysis based on the largest-scale of published literature confirms that post-CCRT yields significant survival benefit and improves local-regional control with tolerable toxicity for patients with esophageal carcinoma. Ivyspring International Publisher 2018-01-01 /pmc/articles/PMC5820926/ /pubmed/29483964 http://dx.doi.org/10.7150/jca.20940 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Kang, Jingjing
Chang, Joe Y.
Sun, Xin
Men, Yu
Zeng, Hongmei
Hui, Zhouguang
Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients
title Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients
title_full Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients
title_fullStr Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients
title_full_unstemmed Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients
title_short Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients
title_sort role of postoperative concurrent chemoradiotherapy for esophageal carcinoma: a meta-analysis of 2165 patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820926/
https://www.ncbi.nlm.nih.gov/pubmed/29483964
http://dx.doi.org/10.7150/jca.20940
work_keys_str_mv AT kangjingjing roleofpostoperativeconcurrentchemoradiotherapyforesophagealcarcinomaametaanalysisof2165patients
AT changjoey roleofpostoperativeconcurrentchemoradiotherapyforesophagealcarcinomaametaanalysisof2165patients
AT sunxin roleofpostoperativeconcurrentchemoradiotherapyforesophagealcarcinomaametaanalysisof2165patients
AT menyu roleofpostoperativeconcurrentchemoradiotherapyforesophagealcarcinomaametaanalysisof2165patients
AT zenghongmei roleofpostoperativeconcurrentchemoradiotherapyforesophagealcarcinomaametaanalysisof2165patients
AT huizhouguang roleofpostoperativeconcurrentchemoradiotherapyforesophagealcarcinomaametaanalysisof2165patients